What is Kiora Pharmaceuticals, Inc.'s earnings per share (EPS)?

Kiora Pharmaceuticals, Inc. (KPRX) reported diluted earnings per share of -$2.64 for fiscal year 2025. This represents a -403.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Kiora Pharmaceuticals, Inc. (KPRX) Financials

KPRX

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$11K -401.4% YoY

EPS (Diluted) -$2.64 -403.4% YoY

Free Cash Flow -$10.1M -217.8% YoY

Market Cap $10.6M as of Oct 17, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.6x on $16.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Newest figures come from the 10-K for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KPRX SEC filings page.

Kiora Pharmaceuticals, Inc. (KPRX) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KPRX FY2025 2026-10-04

Kiora's reported FY2024 profit came with substantial investment and financing activity, revealing a development-stage business rather than steady recurring revenue.

FY2024 operating cash flow of $8.6M nearly doubled operating income of $4.5M, indicating unusually strong cash conversion in the reported year. However, the same year paired $22.7M of investing outflows with $15.5M of financing inflows, so liquidity depended on capital activity alongside operations rather than recurring revenue alone.

R&D was $7.8M against $16.0M of revenue, showing development spending consumed a large share of the commercial base. SG&A was $5.5M, yet operating margin reached 28.2%; that combination suggests FY2024 profitability was not simply the result of a low-cost operating structure.

Current ratio was 4.9x and debt-to-equity was 0.4x, indicating modest leverage alongside ample short-term coverage. The reported liquidity comparison equaled 20.6 months of annual outflow, a historical balance-to-outflow measure rather than a forecast.

Financial Health Signals

Financial health score not available

Kiora Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-8.97

Kiora Pharmaceuticals, Inc. scores -8.97, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($10.6M) relative to total liabilities ($8.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Kiora Pharmaceuticals, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Kiora Pharmaceuticals, Inc. reported a net loss of $11K while operations used $10.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Kiora Pharmaceuticals, Inc. reported an operating loss of $12.8M against $20K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$2.2M

YoY+7.9%

QoQ+11.9%

Kiora Pharmaceuticals, Inc.'s EBITDA was -$2.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.9% from the same quarter a year earlier. Against the prior quarter it is up 11.9%.

Net Income

-$2.1M

YoY+3.4%

QoQ+14.0%

Kiora Pharmaceuticals, Inc. reported -$2.1M in net income in Q2 2026. This represents an increase of 3.4% from the same quarter a year earlier. Against the prior quarter it is up 14.0%.

EPS (Diluted)

-$0.34

QoQ+41.4%

Kiora Pharmaceuticals, Inc. earned -$0.34 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 41.4%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$1.9M

YoY+50.1%

QoQ+39.5%

Kiora Pharmaceuticals, Inc. recorded an outflow of $1.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 50.1% from the same quarter a year earlier. Against the prior quarter it is up 39.5%.

Cash & Debt

$7.1M

YoY+588.2%

QoQ-35.4%

5Y CAGR+14.1%

10Y CAGR-1.3%

Kiora Pharmaceuticals, Inc. held $7.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ-0.2%

5Y CAGR-18.9%

10Y CAGR-6.8%

Kiora Pharmaceuticals, Inc. had 4M shares outstanding in Q2 2026. Against the prior quarter it is down 0.2%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-12.3%

YoY-2.6pp

QoQ+5.0pp

Kiora Pharmaceuticals, Inc.'s ROE was -12.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.0 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$2.1M

YoY-19.8%

QoQ-2.2%

Kiora Pharmaceuticals, Inc. invested $2.1M in research and development in Q2 2026. This represents a decrease of 19.8% from the same quarter a year earlier. Against the prior quarter it is down 2.2%.

Capital Expenditures

$23K

YoY-27.1%

QoQ+367.4%

Kiora Pharmaceuticals, Inc. invested $23K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 27.1% from the same quarter a year earlier. Against the prior quarter it is up 367.4%.

Share Buybacks

Not reported for Q2 2026.

KPRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KPRX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	N/A	$0-100.0%	$16.0M	$0	N/A	$0-100.0%	$12K-99.6%	$2.7M+62.5%	$1.7M+305.5%	$408K-39.1%	$669K	$0	N/A
R&D Expenses	N/A	$10.8M+37.5%	$7.8M+94.7%	$4.0M+16.8%	$3.4M-35.5%	$5.4M+50.0%	$3.6M-33.8%	$5.4M-33.1%	$8.1M-22.0%	$10.3M+22.7%	$8.4M+210.0%	$2.7M+411.6%	$531K
SG&A Expenses	N/A	$5.7M+3.7%	$5.5M+18.9%	$4.7M-43.7%	$8.3M+55.5%	$5.3M+14.3%	$4.7M+5.7%	$4.4M-0.8%	$4.4M-4.2%	$4.6M-17.1%	$5.6M+41.2%	$4.0M+105.1%	$1.9M
Operating Income	N/A	-$12.8M-384.5%	$4.5M+135.8%	-$12.6M-2.3%	-$12.3M+13.5%	-$14.2M-107.3%	-$6.9M	N/A	-$10.8M	N/A	N/A	N/A	N/A
EBITDA	N/A	-$12.8M-382.7%	$4.5M+136.1%	-$12.5M-2.2%	-$12.3M+13.5%	-$14.2M-107.6%	-$6.8M	N/A	-$10.8M	N/A	N/A	N/A	N/A
Interest Expense	N/A	$20K-6.9%	$21K+92.7%	$11K+29.5%	$9K+25.5%	$7K+63.7%	$4K+1188.0%	$325-68.8%	$1K-14.4%	$1K+341.8%	$275-100.0%	$1.9M+337.9%	$442K
Income Tax	N/A	-$1.3M-162.1%	$2.1M+2186.3%	$90K+179.9%	-$113K+41.3%	-$193K-1697.7%	$12K-87.4%	$95K+10.9%	$86K+106.4%	-$1.3M	$0	N/A	N/A
Net Income	N/A	-$11K-401.4%	$4K+128.7%	-$13K+99.9%	-$13.6M+1.4%	-$13.8M-100.7%	-$6.9M+3.3%	-$7.1M+34.4%	-$10.8M+18.2%	-$13.2M+0.9%	-$13.3M-59.1%	-$8.4M-440.6%	-$1.6M
EPS (Basic)	N/A	-$2.60-379.6%	$0.93+3927.2%	-$0.02+99.9%	-$18.55+67.5%	-$57.12-3733.6%	-$1.49	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$2.51	-$2.64-403.4%	$0.87	-$0.02	-$18.55	-$57.12	-$1.49	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	4M-0.5%	4M	538,007	732,303	241,099	5M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	$0	$0-100.0%	$0-100.0%	N/A	$0
R&D Expenses	$2.1M-19.8%	$2.1M-16.1%	N/A	$2.7M+24.9%	$2.6M+26.4%	$2.5M+50.3%	N/A	$2.2M+101.4%
SG&A Expenses	$1.4M+2.2%	$1.6M+8.2%	N/A	$1.4M+4.5%	$1.4M-12.0%	$1.5M+14.9%	N/A	$1.4M-2.5%
Operating Income	-$2.2M+7.6%	-$2.5M-7.7%	N/A	-$794K+77.9%	-$2.4M+5.8%	-$2.3M-117.6%	N/A	-$3.6M+39.1%
EBITDA	-$2.2M+7.9%	-$2.5M-7.3%	N/A	-$784K+78.2%	-$2.4M+5.7%	-$2.3M-117.6%	N/A	-$3.6M+39.1%
Income Tax	$0+100.0%	$0-100.0%	N/A	-$643K	-$112K	$123K	N/A	$0
Net Income	-$2.1M+3.4%	-$2.4M-10.3%	N/A	$27K+100.8%	-$2.2M+3.1%	-$2.2M-116.3%	N/A	-$3.4M+40.8%
EPS (Basic)	-$0.34+37.0%	-$0.58-11.5%	-$1.56-35.7%	$0.01+101.2%	-$0.54-1.9%	-$0.52-111.1%	-$1.15-2975.0%	-$0.81+88.9%
EPS (Diluted)	-$0.34	-$0.58-11.5%	-$1.60-53.8%	$0.01	-$0.54-1.9%	-$0.52	-$1.04	-$0.81
Diluted Shares (Avg)	6M	4M-1.0%	N/A	4M	4M-4.4%	4M	N/A	4M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

KPRX Balance Sheet

KPRX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$24.3M-33.5%	$36.5M+166.1%	$13.7M-26.6%	$18.7M-7.2%	$20.1M+31.5%	$15.3M+51.3%	$10.1M-29.2%	$14.3M-0.2%	$14.3M+47.0%	$9.7M+2.3%	$9.5M+576.0%	$1.4M
Current Assets	$21.7M-26.8%	$29.7M+527.0%	$4.7M-38.3%	$7.7M-14.6%	$9.0M+420.8%	$1.7M-60.1%	$4.3M-49.0%	$8.5M+0.2%	$8.5M+103.6%	$4.2M-56.0%	$9.4M+4219.0%	$219K
Cash & Equivalents	$8.7M+129.3%	$3.8M+54.5%	$2.5M-58.8%	$6.0M-24.1%	$7.9M+562.5%	$1.2M-68.6%	$3.8M-52.8%	$8.0M+2.5%	$7.8M+114.7%	$3.6M-56.7%	$8.4M+4926.4%	$167K
Short-Term Investments	$8.4M-63.5%	$23.0M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$1.5M+153.3%	$601K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	$0	$0-100.0%	$3.6M+138.0%	$1.5M0.0%	$1.5M0.0%	$1.5M	N/A	N/A	N/A
Total Liabilities	$8.1M-24.2%	$10.7M+41.1%	$7.6M+4.6%	$7.3M+31.0%	$5.6M-0.4%	$5.6M+59.7%	$3.5M-34.7%	$5.3M-67.1%	$16.2M+61.4%	$10.1M+194.1%	$3.4M-92.9%	$48.2M
Current Liabilities	$3.6M-39.6%	$6.0M+267.7%	$1.6M-50.1%	$3.3M+103.3%	$1.6M-18.9%	$2.0M+40.3%	$1.4M-63.4%	$3.9M-73.9%	$14.8M+103.0%	$7.3M+113.6%	$3.4M-31.9%	$5.0M
Non-Current Liabilities	$4.5M-4.7%	$4.7M-21.0%	$6.0M+49.3%	$4.0M+1.4%	$3.9M+9.8%	$3.6M+73.0%	$2.1M+40.2%	$1.5M+5.8%	$1.4M-49.2%	$2.8M	$0-100.0%	$43.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$278K	$0	N/A	N/A	N/A	N/A	N/A
Total Equity	$16.1M-37.4%	$25.8M+321.6%	$6.1M-46.4%	$11.4M-21.8%	$14.6M+49.8%	$9.7M+46.9%	$6.6M-25.9%	$8.9M+563.8%	-$1.9M-484.9%	-$329K-105.4%	$6.1M+113.0%	-$46.8M
Retained Earnings	-$154.2M-7.6%	-$143.4M+2.4%	-$147.0M-9.3%	-$134.5M-11.2%	-$120.9M-12.9%	-$107.1M-6.8%	-$100.2M-7.6%	-$93.2M-1.5%	-$91.8M-16.8%	-$78.6M-20.4%	-$65.3M-14.8%	-$56.9M

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$23.8M-25.6%	$21.2M-37.6%	$24.3M-33.5%	$29.9M-22.5%	$31.9M-21.7%	$34.0M-19.8%	$36.5M+166.1%	$38.5M+142.3%
Current Assets	$21.3M-14.0%	$18.7M-31.1%	$21.7M-26.8%	$22.7M-28.3%	$24.7M-22.3%	$27.1M-19.0%	$29.7M+527.0%	$31.7M+353.3%
Cash & Equivalents	$7.1M+588.2%	$11.0M+190.5%	$8.7M+129.3%	$5.5M-2.3%	$1.0M-84.4%	$3.8M-87.9%	$3.8M+54.5%	$5.6M+4.4%
Short-Term Investments	$9.8M-50.3%	$2.9M-85.7%	$8.4M-63.5%	$13.9M-40.7%	$19.6M-7.6%	$20.3M	$23.0M	$23.4M
Accounts Receivable	$1.1M-54.9%	$1.5M+15.4%	$1.5M+153.3%	$1.2M-32.0%	$2.4M+80.3%	$1.3M+604.4%	$601K	$1.8M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$6.9M-29.5%	$7.3M-29.3%	$8.1M-24.2%	$7.5M-12.1%	$9.8M+27.3%	$10.3M+36.9%	$10.7M+41.1%	$8.5M+8.8%
Current Liabilities	$2.4M-25.6%	$2.8M-46.9%	$3.6M-39.6%	$2.6M-26.9%	$3.2M+92.4%	$5.3M+231.1%	$6.0M+267.7%	$3.5M+67.9%
Non-Current Liabilities	$4.5M-31.4%	$4.5M-10.9%	$4.5M-4.7%	$4.9M-1.6%	$6.6M+9.5%	$5.0M-15.1%	$4.7M-21.0%	$5.0M-13.0%
Total Equity	$16.9M-23.8%	$13.9M-41.2%	$16.1M-37.4%	$22.4M-25.4%	$22.1M-33.2%	$23.7M-32.1%	$25.8M+321.6%	$30.0M+270.6%
Retained Earnings	-$158.7M-7.4%	-$156.6M-7.6%	-$154.2M-7.6%	-$147.7M-6.1%	-$147.7M-8.8%	-$145.6M-9.0%	-$143.4M+2.4%	-$139.2M+3.8%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

KPRX Cash Flow Statement

KPRX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$8.5M	-$10.0M-216.4%	$8.6M+189.6%	-$9.6M+8.4%	-$10.4M+2.3%	-$10.7M-45.9%	-$7.3M+10.3%	-$8.2M+24.8%	-$10.8M-67.7%	-$6.5M+23.1%	-$8.4M-88.7%	-$4.5M-369.1%	-$951K
Depreciation & Amortization	N/A	$25K+29.1%	$19K-62.9%	$52K+24.5%	$42K-8.1%	$45K+35.6%	$33K-35.4%	$52K+34.3%	$38K+99.5%	$19K+272.0%	$5K+312.5%	$1K-27.1%	$2K
Stock-Based Compensation	N/A	$900K+37.1%	$657K-13.0%	$755K+63.2%	$462K-45.1%	$842K+16.4%	$724K-15.1%	$852K-2.6%	$875K+0.6%	$870K+70.3%	$511K-58.3%	$1.2M+4467.2%	$27K
Capital Expenditures	$107K	$111K+1670.9%	$6K	$0	$0-100.0%	$64K+218.1%	$20K	$0-100.0%	$20K-45.9%	$37K	$0	N/A	N/A
Free Cash Flow	-$8.6M	-$10.1M-217.8%	$8.6M+189.5%	-$9.6M+8.4%	-$10.4M+2.9%	-$10.7M-46.4%	-$7.3M+10.0%	-$8.2M+24.9%	-$10.9M-67.0%	-$6.5M+22.7%	-$8.4M	N/A	N/A
Investing Cash Flow	$9.6M	$14.4M+163.7%	-$22.7M	$0-100.0%	$6K+104.1%	-$157K+35.8%	-$244K	$0+100.0%	-$270K-629.7%	-$37K-121.2%	$175K	N/A	N/A
Financing Cash Flow	$4.9M	$266K-98.3%	$15.5M+159.8%	$6.0M-30.8%	$8.6M-51.0%	$17.6M+251.8%	$5.0M+27.5%	$3.9M-65.3%	$11.3M+5.9%	$10.7M+205.1%	$3.5M	N/A	N/A

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.9M+50.3%	-$3.2M-16.9%	-$2.2M+3.2%	-$1.3M-238.4%	-$3.8M-1.9%	-$2.7M-119.8%	-$2.3M+12.7%	$920K+136.5%
Depreciation & Amortization	$11K+213.8%	$11K+3221.7%	$11K+77.7%	$11K+403.7%	$3K-45.9%	$318-93.5%	$6K-25.5%	$2K-81.5%
Stock-Based Compensation	N/A	$210K+41.0%	N/A	N/A	N/A	$149K-15.3%	N/A	N/A
Capital Expenditures	$23K-27.1%	$5K	$78K+73.6%	$431	$32K	$0	-$45K	$0
Free Cash Flow	-$1.9M+50.1%	-$3.2M-17.1%	-$2.3M+1.7%	-$1.3M-238.4%	-$3.8M	-$2.7M	-$2.3M+11.0%	$920K+136.5%
Investing Cash Flow	-$6.9M-1137.3%	$5.4M+102.1%	$5.3M+1008.2%	$5.7M+398.9%	$664K+103.1%	$2.7M	$483K	-$1.9M
Financing Cash Flow	$4.9M+1753.7%	-$842	$296	$0	$265K+5.9%	$0-100.0%	$0+100.0%	$0

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

KPRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KPRX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Margin	N/A	28.1%	N/A	N/A	N/A	-56960.5%	N/A	-656.3%	N/A	N/A	N/A	N/A
Net Margin	N/A	0.0%	N/A	N/A	N/A	-56901.6%	-264.2%	-654.2%	-3243.5%	-1993.8%	N/A	N/A
Return on Equity	-0.1%-0.1pp	0.0%+0.2pp	-0.2%+118.9pp	-119.1%-24.6pp	-94.5%-23.9pp	-70.5%+36.6pp	-107.2%+13.8pp	-121.0%	N/A	N/A	-137.8%	N/A
Return on Assets	0.0%-0.1pp	0.0%+0.1pp	-0.1%+72.6pp	-72.7%-4.3pp	-68.4%-23.6pp	-44.8%+25.3pp	-70.2%+5.5pp	-75.7%+16.7pp	-92.4%+44.7pp	-137.1%-48.9pp	-88.2%+22.1pp	-110.3%
Current Ratio	5.99+1.0x	4.94+2.0x	2.90+0.6x	2.35-3.2x	5.59+4.7x	0.87-2.2x	3.06+0.9x	2.19+1.6x	0.570.0x	0.57-2.2x	2.76+2.7x	0.04
Debt-to-Equity	0.50+0.1x	0.42-0.8x	1.24+0.6x	0.64+0.3x	0.38+0.4x	0.030.0x	0.00-0.6x	0.60	N/A	N/A	0.56	N/A
Asset Turnover	0.00-0.4x	0.44+0.4x	0.00	N/A	0.000.0x	0.00-0.3x	0.27+0.1x	0.12+0.1x	0.030.0x	0.07+0.1x	0.00	N/A
FCF Margin	N/A	53.4%	N/A	N/A	N/A	-60844.6%	-303.6%	-657.4%	-1596.4%	-1257.1%	N/A	N/A

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-12.3%-2.6pp	-17.3%-8.1pp	N/A	0.1%+11.5pp	-9.7%-3.0pp	-9.3%-47.8pp	N/A	-11.4%+59.7pp
Return on Assets	-8.7%-2.0pp	-11.4%-4.9pp	N/A	0.1%+8.9pp	-6.7%-1.3pp	-6.5%-38.1pp	N/A	-8.9%+27.4pp
Current Ratio	8.97+1.2x	6.68+1.5x	5.99+1.0x	8.79-0.2x	7.76-11.5x	5.14-15.9x	4.94+2.0x	8.97+5.6x
Debt-to-Equity	0.410.0x	0.52+0.1x	0.50+0.1x	0.33+0.1x	0.44+0.2x	0.44+0.2x	0.42-0.8x	0.28-0.7x
Asset Turnover	N/A	N/A	N/A	0.000.0x	0.000.0x	0.00-0.4x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Kiora Pharmaceuticals, Inc. KPRX	FY2025	$0	-$11K	N/A	$10.6M	—
Aprea Therapeutics, Inc. APRE	FY2025	N/A	-$12.6M	N/A	$7.4M	—
Genprex, Inc. GNPX	FY2025	N/A	-$16.2M	N/A	$1.7M	—
Processa Pharmaceuticals, Inc. PCSA	FY2025	N/A	-$13.6M	N/A	$4.7M	—
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock CYCCP	FY2025	$747K	$3.0M	N/A	$9.6M	—
IN8bio, Inc. INAB	FY2025	N/A	-$19.4M	N/A	$10.9M	—

Where Kiora Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

What is Kiora Pharmaceuticals, Inc.'s annual revenue?

Kiora Pharmaceuticals, Inc. (KPRX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Kiora Pharmaceuticals, Inc.'s revenue growing?

Kiora Pharmaceuticals, Inc. (KPRX) revenue declined by 100.0% year-over-year, from $16.0M to $0 in fiscal year 2025.

Is Kiora Pharmaceuticals, Inc. profitable?

No, Kiora Pharmaceuticals, Inc. (KPRX) reported a net income of -$11K in fiscal year 2025.

What is Kiora Pharmaceuticals, Inc.'s EBITDA?

Kiora Pharmaceuticals, Inc. (KPRX) had EBITDA of -$12.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Kiora Pharmaceuticals, Inc.'s return on equity (ROE)?

Kiora Pharmaceuticals, Inc. (KPRX) has a return on equity of -0.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Kiora Pharmaceuticals, Inc.'s free cash flow?

Kiora Pharmaceuticals, Inc. (KPRX) recorded an outflow of $10.1M in free cash flow during fiscal year 2025. This represents a -217.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Kiora Pharmaceuticals, Inc.'s operating cash flow?

Kiora Pharmaceuticals, Inc. (KPRX) recorded an outflow of $10.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Kiora Pharmaceuticals, Inc.'s total assets?

Kiora Pharmaceuticals, Inc. (KPRX) had $24.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Kiora Pharmaceuticals, Inc.'s capital expenditures?

Kiora Pharmaceuticals, Inc. (KPRX) invested $111K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Kiora Pharmaceuticals, Inc. spend on research and development?

Kiora Pharmaceuticals, Inc. (KPRX) invested $10.8M in research and development during fiscal year 2025.

How many shares does Kiora Pharmaceuticals, Inc. have outstanding?

Kiora Pharmaceuticals, Inc. (KPRX) had 4M shares outstanding as of fiscal year 2025.

What is Kiora Pharmaceuticals, Inc.'s current ratio?

Kiora Pharmaceuticals, Inc. (KPRX) had a current ratio of 5.99 as of fiscal year 2025, which is generally considered healthy.

What is Kiora Pharmaceuticals, Inc.'s debt-to-equity ratio?

Kiora Pharmaceuticals, Inc. (KPRX) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Kiora Pharmaceuticals, Inc.'s return on assets (ROA)?

Kiora Pharmaceuticals, Inc. (KPRX) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Kiora Pharmaceuticals, Inc.'s P/E ratio?

Kiora Pharmaceuticals, Inc. (KPRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $10.6M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Kiora Pharmaceuticals, Inc.'s price-to-sales ratio?

Kiora Pharmaceuticals, Inc. (KPRX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $10.6M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Kiora Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Kiora Pharmaceuticals, Inc. (KPRX) held $17.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.0M over that year. Dividing the one by the other, the reported balance equals about 21 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Kiora Pharmaceuticals, Inc.'s Altman Z-Score?

Kiora Pharmaceuticals, Inc. (KPRX) has an Altman Z-Score of -8.97, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Kiora Pharmaceuticals, Inc.'s Piotroski F-Score?

Kiora Pharmaceuticals, Inc. (KPRX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Kiora Pharmaceuticals, Inc.'s earnings high quality?

Kiora Pharmaceuticals, Inc. (KPRX) reported a net loss of $11K while operations used $10.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Kiora Pharmaceuticals, Inc. cover its interest payments?

Kiora Pharmaceuticals, Inc. (KPRX) reported an operating loss of $12.8M against $20K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.